Analysis of circulating tumor markers in blood in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ALCINA 5 is a small-cohort, interventional study that uses blood samples to analyze circulating tumor biomarkers in patients with invasive tumors, including non-small cell lung cancer. Researchers compare blood markers with tumor tissue when available and examine how marker levels change in relation to events like chemotherapy, biopsy, or surgery. The aim is to determine the feasibility and potential utility of liquid biopsy markers and their kinetics for clinical decision-making. If initial results are promising, further larger studies may be planned under applicable approvals. The study is conducted at a French cancer center with basic inclusion and exclusion criteria focusing on adults who can consent and are affiliated with the social protection system.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
2. 18 years old or higher ?
3. Patient who has provided informed, written, and explicit consent,
4. Patient affiliated with a French Social Protection System.

   In the case of a tumor biopsy:
5. Tumor considered as accessible by biopsy,
6. Normal hemostasis assessment (PT, APTT, platelets),
7. No anticoagulant or antiaggregant treatment for the biopsy.

Exclusion Criteria:

1. Pregnant woman and/or breast-feeding,
2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
3. Private persons of freedom or under guardianship,
4. Patient with a history of other invasive cancers within the 5 years preceding inclusion.

Where it's running

• Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
  Montpellier, France, France Recruiting

Study contacts

• Study coordinator: Emmanuelle TEXIER
• Email: emmanuelle.texier@icm.unicancer.fr
• Phone: 467613102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations

  This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07405190

• Personalized exercise plan for cancer survivors

  This study tests a personalized, physician-guided exercise program for adults who have completed cancer treatment, to see if a safe, structured plan can be implemented in routine care.

  Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan · NCT07751783

• Abdominal pressure device to control breathing during stereotactic radiotherapy for peripheral non-small cell lung cancer

  This project tries an abdominal pressure device to reduce breathing-related tumor movement during stereotactic radiotherapy for people with solitary peripheral non-small cell lung cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07561567

• Combining nutrition checks and muscle measurements to predict outcomes after lung cancer surgery

  This project will test whether combining nutrition tests and muscle scans can predict recovery, complications, and short-term outcomes in adults having lung cancer surgery.

  Recruiting Ondokuz Mayıs University · Samsun, Samsun · NCT07500376

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Phase II test of SKB571 for advanced non-small cell lung cancer

  This study will test SKB571 given alone in adults with advanced non-small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou and 1 other locations · NCT07230405

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.